JP2017533969A - Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 - Google Patents

Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 Download PDF

Info

Publication number
JP2017533969A
JP2017533969A JP2017544552A JP2017544552A JP2017533969A JP 2017533969 A JP2017533969 A JP 2017533969A JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017533969 A JP2017533969 A JP 2017533969A
Authority
JP
Japan
Prior art keywords
naca
administered
retinitis pigmentosa
acid
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017544552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533969A5 (enExample
Inventor
ピーター エー カンポキアーロ
ピーター エー カンポキアーロ
ダニエル ハートマン
ダニエル ハートマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nacuity Pharmaceuticals Inc
Original Assignee
Nacuity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nacuity Pharmaceuticals Inc filed Critical Nacuity Pharmaceuticals Inc
Publication of JP2017533969A publication Critical patent/JP2017533969A/ja
Publication of JP2017533969A5 publication Critical patent/JP2017533969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2017544552A 2014-11-07 2015-11-06 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 Pending JP2017533969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076594P 2014-11-07 2014-11-07
US62/076,594 2014-11-07
PCT/US2015/059589 WO2016073931A1 (en) 2014-11-07 2015-11-06 Treatment of retinitis pigmentosa with n-acetylcysteine amide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019191044A Division JP2020023549A (ja) 2014-11-07 2019-10-18 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療

Publications (2)

Publication Number Publication Date
JP2017533969A true JP2017533969A (ja) 2017-11-16
JP2017533969A5 JP2017533969A5 (enExample) 2018-04-19

Family

ID=55909913

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017544552A Pending JP2017533969A (ja) 2014-11-07 2015-11-06 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2019191044A Pending JP2020023549A (ja) 2014-11-07 2019-10-18 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2021147283A Pending JP2021193119A (ja) 2014-11-07 2021-09-10 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2023127716A Pending JP2023145734A (ja) 2014-11-07 2023-08-04 Ｎ－アセチルシステインアミドによる網膜色素変性症の治療
JP2025126989A Pending JP2025160381A (ja) 2014-11-07 2025-07-30 Ｎ－アセチルシステインアミドによる網膜色素変性症の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019191044A Pending JP2020023549A (ja) 2014-11-07 2019-10-18 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2021147283A Pending JP2021193119A (ja) 2014-11-07 2021-09-10 Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2023127716A Pending JP2023145734A (ja) 2014-11-07 2023-08-04 Ｎ－アセチルシステインアミドによる網膜色素変性症の治療
JP2025126989A Pending JP2025160381A (ja) 2014-11-07 2025-07-30 Ｎ－アセチルシステインアミドによる網膜色素変性症の治療

Country Status (11)

Country Link
US (2) US20180296503A1 (enExample)
EP (2) EP3214934A4 (enExample)
JP (5) JP2017533969A (enExample)
KR (3) KR20230152177A (enExample)
CN (2) CN107426997A (enExample)
AU (4) AU2015342831B2 (enExample)
BR (1) BR112017009584A2 (enExample)
CA (1) CA2967327C (enExample)
HK (1) HK1252822A1 (enExample)
RU (1) RU2711913C2 (enExample)
WO (2) WO2016073931A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511369A (ja) * 2020-01-24 2023-03-17 ナキュイティ ファーマシューティカルズ， インク． 酸化ストレスの疾患及び傷害の治療のためのプロドラッグ

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
RU2711913C2 (ru) 2014-11-07 2020-01-24 Дзе Джонс Хопкинс Юниверсити Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
US11268964B2 (en) 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
CN111386255B (zh) 2017-09-20 2021-11-23 纳崔泰制药有限公司 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) * 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20190151271A1 (en) * 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
WO2020011607A1 (en) * 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN109096161B (zh) * 2018-08-24 2020-10-27 武汉远大弘元股份有限公司 一种n-乙酰半胱氨酸的制备方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US11766413B2 (en) 2019-01-11 2023-09-26 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340147A (en) 1965-06-28 1967-09-05 Mead Johnson & Co Amides of n-acylated cysteines
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
WO2002100293A2 (en) 2001-06-13 2002-12-19 Webb-Waring Institute For Biomedical Research A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
BE1014949A3 (fr) 2001-08-14 2004-07-06 Probiox Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
WO2004012652A2 (en) 2002-08-02 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of multiple sclerosis with brain targeted anti oxidant compounds
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
JP2005350405A (ja) 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
KR20080028357A (ko) 2005-04-21 2008-03-31 글렌 에이. 골드스타인 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
JP4840804B2 (ja) 2006-01-20 2011-12-21 学校法人慶應義塾 酸化ストレスの判定方法
WO2010048716A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20120150029A1 (en) 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
US9173423B2 (en) 2009-07-31 2015-11-03 The Iams Company Animal food kibble with electrostatically adhered dusting
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
EP2397125A1 (en) 2010-06-15 2011-12-21 Histocell, S.L. Antioxidant composition
US20120142550A1 (en) 2010-12-06 2012-06-07 Zehnder James L Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
WO2013138744A1 (en) 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
US20150328337A1 (en) 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
EP3122342B1 (en) 2014-03-28 2020-09-23 NaCuity Pharmaceuticals, Inc. Method for the preparation of n-acetyl cysteine amide
RU2711913C2 (ru) 2014-11-07 2020-01-24 Дзе Джонс Хопкинс Юниверсити Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
US11268964B2 (en) 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CN111386255B (zh) 2017-09-20 2021-11-23 纳崔泰制药有限公司 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法
CN118924717A (zh) 2017-09-20 2024-11-12 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
WO2019060704A1 (en) 2017-09-22 2019-03-28 University Of Florida Research Foundation DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019097434A1 (en) 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
US20190151271A1 (en) 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
CN108618993B (zh) 2018-07-16 2021-07-27 广东格烯生物科技股份有限公司 一种美白组合物及其制备方法和应用
US20210369649A1 (en) 2018-11-16 2021-12-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
US11766413B2 (en) 2019-01-11 2023-09-26 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONG A. ET AL.: "Compared with N-acetylcysteine(NAC), N-Acetylcysteine Amide(NACA) Provides Increased Protection of C", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. Vol. 55, Issue 13, JPN6018046241, April 2014 (2014-04-01), pages 1736, ISSN: 0004058757 *
PNAS, vol. 103, no. 30, JPN6018046240, 2006, pages 11300 - 11305, ISSN: 0004058758 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511369A (ja) * 2020-01-24 2023-03-17 ナキュイティ ファーマシューティカルズ， インク． 酸化ストレスの疾患及び傷害の治療のためのプロドラッグ

Also Published As

Publication number Publication date
US20170333375A1 (en) 2017-11-23
WO2016073931A1 (en) 2016-05-12
JP2021193119A (ja) 2021-12-23
JP2020023549A (ja) 2020-02-13
BR112017009584A2 (pt) 2017-12-26
RU2017119230A (ru) 2018-12-10
US20180296503A1 (en) 2018-10-18
AU2015342831B2 (en) 2019-09-12
AU2015342831A1 (en) 2017-05-25
WO2016073829A2 (en) 2016-05-12
EP3214934A1 (en) 2017-09-13
CA2967327C (en) 2020-04-28
AU2019261762A1 (en) 2019-11-28
AU2021225263B2 (en) 2023-11-02
WO2016073829A9 (en) 2016-06-23
JP2023145734A (ja) 2023-10-11
KR20220039853A (ko) 2022-03-29
EP4000612A1 (en) 2022-05-25
RU2711913C2 (ru) 2020-01-24
KR20170109527A (ko) 2017-09-29
EP3214934A4 (en) 2018-06-20
US12472157B2 (en) 2025-11-18
CN108498495A (zh) 2018-09-07
AU2019261762B2 (en) 2021-06-10
AU2021225263A1 (en) 2021-09-30
JP2025160381A (ja) 2025-10-22
HK1252822A1 (zh) 2019-06-06
RU2017119230A3 (enExample) 2018-12-10
AU2024200436A1 (en) 2024-02-08
KR20230152177A (ko) 2023-11-02
CA2967327A1 (en) 2016-05-12
CN107426997A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
AU2021225263B2 (en) Treatment of retinitis pigmentosa with n-acetylcysteine amide
JP7631200B2 (ja) 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
US11766413B2 (en) Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
US20210228509A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
JP2023529190A (ja) シスチン症の治療
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
US20230381120A1 (en) Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190620